Ms Lesion News Today

"Serious infections did not vary by age, and there were too few serious events to identify any age-related trends by specific TEAE," the authors reported.

Data from a phase 3 trial suggest high-dose vitamin D does not prevent relapse in patients with RRMS. However, at least one expert suggests the studys exclusion criteria may have been too broad.

New recommendations help clinicians communicate technical information to help patients with multiple sclerosis achieve better understanding and self-care.

Although serum glial fibrillary acid protein (GFAP) could be a useful complement to the multiple sclerosis biomarker neurofilament light chain (NfL), it is not ready for the clinic, experts say.

The first randomized trial of a disease-modifying therapy in radiological isolated syndrome, the earliest pre-clinical phase of MS, suggests dimethyl fumarate reduced the risk of a first clinical event by 80%.

The first randomized trial to examine if older adults with multiple sclerosis can discontinue disease-modifying therapy after years of being relapse-free failed to deliver a definitive conclusion.

General neurologists fall short in their knowledge of key multiple sclerosis diagnostic criteria standards compared with MS experts, new findings show, which may be detrimental to patient management.

High serum levels of neurofilament light are associated with an increased risk for disease progression at 2 years. Clinical, MRI, and OCT measures are not associated with this risk, however.

Autologous hematopoietic stem cell transplantation for the treatment of active secondary progressive MS is associated with better disability outcomes than other immunotherapies, a new Italian study suggests.

Updated European guidelines also include a recommendation for siponimod in progressive MS and more detailed information on drug use in pregnancy.